Delivering extraordinary. Empowering ordinary.

BioCryst develops novel oral medicines for rare disease to help patients take part in the everyday activities they enjoy.

Learn More.

Structure-guided Drug Design

Our scientists combine traditional cell biology with medicinal chemistry to design synthetic compounds that bind to specific protein targets to fight disease.

Our Science

Building a Rare Disease Drug Portfolio

We are committed to developing a pipeline of oral drugs for rare diseases, with our initial focus on advancing our next generation kallikrein inhibitor program to treat hereditary angioedema (HAE).

Our Pipeline

BioCryst Investor Relations

Whether you are a potential investor in BioCryst Pharmaceuticals or you are already a shareholder, our investor center is the primary source of information about the company.

Investors

Join Our Team

We are a collection of passionate individuals united by a commitment to scientific excellence combined with an unwavering focus on the needs of our patients.

Job Openings